Universal Ibogaine Inc (IBO) - Total Liabilities
Based on the latest financial reports, Universal Ibogaine Inc (IBO) has total liabilities worth CA$3.73 Million CAD (≈ $2.70 Million USD) as of April 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Universal Ibogaine Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Universal Ibogaine Inc's total liabilities have evolved over time, based on quarterly financial data. See IBO working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Universal Ibogaine Inc Competitors by Total Liabilities
The table below lists competitors of Universal Ibogaine Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Starbox Group Holdings Ltd. Ordinary Shares
NASDAQ:STBX
|
USA | $11.35 Million |
|
Biomotion Sciences Ordinary Shares
NASDAQ:SLXN
|
USA | $4.31 Million |
|
EnSilica PLC
LSE:ENSI
|
UK | GBX21.71 Million |
|
Devolver Digital Inc
LSE:DEVO
|
UK | GBX30.74 Million |
|
Handal Resources Bhd
KLSE:7253
|
Malaysia | RM94.79 Million |
|
Distribution Finance Capital Holdings PLC
LSE:DFCH
|
UK | GBX872.21 Million |
|
NANOSPHERE
F:3NS
|
Germany | €3.45 Million |
|
Strix Group Plc
LSE:KETL
|
UK | GBX131.53 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Universal Ibogaine Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Universal Ibogaine Inc market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 13.72 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.93 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Universal Ibogaine Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Universal Ibogaine Inc (2018–2024)
The table below shows the annual total liabilities of Universal Ibogaine Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-07-31 | CA$3.52 Million ≈ $2.55 Million |
-6.08% |
| 2023-07-31 | CA$3.75 Million ≈ $2.71 Million |
+57.94% |
| 2022-07-31 | CA$2.37 Million ≈ $1.72 Million |
+7.78% |
| 2021-07-31 | CA$2.20 Million ≈ $1.59 Million |
+10042.30% |
| 2020-07-31 | CA$21.72K ≈ $15.71K |
+8.12% |
| 2019-07-31 | CA$20.09K ≈ $14.53K |
-21.01% |
| 2018-07-31 | CA$25.44K ≈ $18.40K |
-- |
About Universal Ibogaine Inc
Universal Ibogaine Inc., a life sciences company, develops, acquires, and operates addiction treatment clinics in Canada. The company also undertakes planned clinical trial for research into the use of ibogaine for addiction treatment. Universal Ibogaine Inc. is headquartered in Calgary, Canada.